RECORD // Company

Keros Therapeutics, Inc.

Built 2026-11-22T05:11:24Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Keros Therapeutics, Inc. · Ctgov · same registered legal name as 'Keros Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • KEROS THERAPEUTICS INC · Epa echo · same registered legal name as 'Keros Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001664710-26-000066

ItemValuePeriodFormFiledAccessionReport
Revenue$40,009,0003 months ended 2026-09-3010-Q2026-11-050001664710-26-0000662026-11-22 05:11 UTCReport an error
Net income (loss)$14,153,0003 months ended 2026-09-3010-Q2026-11-050001664710-26-0000662026-11-22 05:11 UTCReport an error
Cash and cash equivalents$259,464,000at 2026-09-3010-Q2026-11-050001664710-26-0000662026-11-22 05:11 UTCReport an error
Contract liabilities, current (from an earlier report)$155,000at 2025-09-3010-Q2025-11-050001664710-25-0000892026-11-22 05:11 UTCReport an error

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001664710
Ticker
KROS
EIN
811173868
CUSIP
492327101
Record ID
sx:sec:0001664710

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-19SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-19SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
Fiscal year end (MMDD)12312026-11-19SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
Business address1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 024212026-11-19SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
ExchangesNasdaq2026-11-19SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$243,864,0002025-12-3110-K, XBRL Revenues2026-11-22 05:11 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$87,014,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 05:11 UTCReport an error
Total assets (at 2025-12-31)$338,021,0002025-12-3110-K, XBRL Assets2026-11-22 05:11 UTCReport an error
Stockholders' equity (at 2025-12-31)$303,132,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 05:11 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$287,415,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 05:11 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$107,505,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 05:11 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$1,551,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 05:11 UTCReport an error
Operating lease liabilities (at 2025-12-31)$16,883,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 05:11 UTCReport an error
Form D total offering amount (D filed 2020-03-12)$56,000,0572020-03-12D2026-11-22 05:11 UTCReport an error
Form D total amount sold (D filed 2020-03-12)$56,000,0572020-03-12D2026-11-22 05:11 UTCReport an error
Form D industry groupOther2020-03-12D2026-11-22 05:11 UTCReport an error
Form D revenue rangeDecline to Disclose2020-03-12D2026-11-22 05:11 UTCReport an error
Form D date of first sale2020-03-022020-03-12D2026-11-22 05:11 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-16)Share Repurchase Program On November 16, 2026, Keros Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing that the board of directors of the Company has approved a new stock repurchase program for up to $5 million of the Company’s common stock (the “Stock Repurchase”) following receipt of a $20 million development milestone payment under the license agreement with Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) in November 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. As of September 30, 2026, the Company had cash and cash equivalents of $259.5 million. Based on its current operating…2026-11-16SEC EDGAR 8-K 0001664710-26-000072 (text as filed, excerpt)2026-11-22 05:11 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-05)On November 5, 2026, Keros Therapeutics, Inc. (the “Company”) updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company’s website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing…2026-11-05SEC EDGAR 8-K 0001664710-26-000067 (text as filed, excerpt)2026-11-22 05:11 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended September 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and in the accompanying exhibit is not incorporated by reference in any…2026-11-05SEC EDGAR 8-K 0001664710-26-000065 (text as filed, excerpt)2026-11-22 05:11 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-29)On September 29, 2026, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing that it will receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda Pharmaceuticals U.S.A., Inc., following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis and anemia on concurrent ruxolitinib therapy. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information…2026-09-29SEC EDGAR 8-K 0001664710-26-000059 (text as filed, excerpt)2026-11-22 05:11 UTCReport an error
Plan (pension, plan no. 001)KEROS THERAPEUTICS: 151 participants, assets $16,436,4062025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 05:11 UTCReport an error
Largest institutional holder #1 (13F as filed): Nantahala Capital Management, LLC$30,182,9662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$29,898,1202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error
Largest institutional holder #3 (13F as filed): AQR CAPITAL MANAGEMENT LLC$10,356,0922026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error
Largest institutional holder #4 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$8,919,4772026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error
Largest institutional holder #5 (13F as filed): ORBIMED ADVISORS LLC$8,122,9592026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error
Largest institutional holder #6 (13F as filed): FEDERATED HERMES, INC.$7,494,5692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$6,983,1952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error
Largest institutional holder #8 (13F as filed): MACKENZIE FINANCIAL CORP$6,724,2872026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error
Largest institutional holder #9 (13F as filed): Madison Avenue Partners, LP$6,704,4382026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error
Largest institutional holder #10 (13F as filed): Qube Research & Technologies Ltd$6,514,5562026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:11 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.